RALLYBIO CORPORATION Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount
RALLYBIO CORPORATION (RLYB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount of $2.31 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization · last filed 2023-03-06
- RALLYBIO CORPORATION effective income tax rate reconciliation, nondeductible expense, amortization, amount for fiscal 2022 was $2.31M, a 36.85% increase from fiscal 2021.
- RALLYBIO CORPORATION effective income tax rate reconciliation, nondeductible expense, amortization, amount for fiscal 2021 was $1.69M, a 7.57% decline from fiscal 2020.
- RALLYBIO CORPORATION effective income tax rate reconciliation, nondeductible expense, amortization, amount for fiscal 2020 was $1.82M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount 12 month |
|---|---|
| 2022-12-31 | $2.31M 10-K · filed 2023-03-06 |
| 2021-12-31 | $1.69M 10-K · filed 2023-03-06 |
| 2020-12-31 | $1.82M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |